13. Heart Failure and Cardiomyopathies: Clinical 1027-05

1027-05 - THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL

Session
1027 - The Buzz in SGLT2 Inhibitors and Heart Failure
Speakers
Pathway
13. Heart Failure and Cardiomyopathies: Clinical
Presentation Number
1027-05
Presentation Rating
 |